Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 20/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623560 | 0.84 | AGTR2 (0.58) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL4316720 | 0.83 | AGTR2 (0.61) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL27973549 | 0.82 | AGTR2 (0.48) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL557059 | 0.81 | AGTR2 (0.55) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL26127636 | 0.80 | AGTR2 (0.72) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL27985940 | 0.80 | AGTR2 (0.37) | AGTR2AGTR1 | |
| SCHEMBL26128256 | 0.80 | AGTR2 (0.49) | AGTR2AGTR1 | |
| SCHEMBL31476812 | 0.80 | AGTR2 (0.71) | AGTR2AGTR1CYP2C9CYP2B6 | |
| SCHEMBL7123182 | 0.78 | AGTR2 (0.39) | AGTR2AGTR1 | |
| SCHEMBL27973603 | 0.77 | AGTR2 (0.43) | AGTR2AGTR1CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119300823-A | Use of cloth Luo Tide for treating idiopathic pulmonary fibrosis | 维科尔药物公司 | 2025-01-10 | — | — | CN | claimed |
| WO-2024133942-A1 | A METHOD OF TREATING A PATIENT DIAGNOSED WITH AN INTERSTITIAL LUNG DISEASE | VICORE PHARMA AB (SE) | 2024-06-27 | — | — | WO | claimed |
| WO-2023152503-A1 | USE OF BULOXIBUTID FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | VICORE PHARMA AB (SE) | 2023-08-17 | — | — | WO | claimed |
| EP-4138789-A1 | NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATION | Vicore Pharma AB (SE) | 2023-03-01 | — | — | EP | claimed |
| EP-4138788-A1 | NEW CAPSULE COMPOSITION FOR PERORAL ADMINISTRATION | Vicore Pharma AB (SE) | 2023-03-01 | — | — | EP | claimed |
| EP-4138790-A1 | NEW DRY POWDER COMPOSITION FOR PERORAL ADMINISTRATION | Vicore Pharma AB (SE) | 2023-03-01 | — | — | EP | claimed |
| CN-115605201-A | New use of angiotensin II type 2 receptor agonists | 维科尔药物公司（SE） | 2023-01-13 | — | — | CN | claimed |
| WO-2021214487-A1 | NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATION | VICORE PHARMA AB (SE) | 2021-10-28 | — | — | WO | claimed |
| WO-2021214486-A1 | NEW CAPSULE COMPOSITION FOR PERORAL ADMINISTRATION | VICORE PHARMA AB (SE) | 2021-10-28 | — | — | WO | claimed |
| WO-2021214488-A1 | NEW DRY POWDER COMPOSITION FOR PERORAL ADMINISTRATION | VICORE PHARMA AB (SE) | 2021-10-28 | — | — | WO | claimed |
| EP-3876902-A1 | NEW COMPOSITION COMPRISING AMORPHOUS NANOPOROUS SILICA PARTICLES | Vicore Pharma AB (SE) | 2021-09-15 | — | — | EP | claimed |
| WO-2021105695-A1 | NEW USE OF ANGIOTENSIN II RECEPTOR AGONIST | VICORE PHARMA AB (SE) | 2021-06-03 | — | — | WO | claimed |
| WO-2019183513-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF MUSCULAR DYSTROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-09-26 | — | — | WO | claimed |
| WO-2019183513-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF MUSCULAR DYSTROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-3229839-A1 | NEW METHODS AND USES | Vicore Pharma AB (SE) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092329-A1 | NEW METHODS AND USES | VICORE PHARMA AB (SE) | 2016-06-16 | — | — | WO | disclosed |
| EP-1869023-B1 | NEW TRICYCLIC ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2012-01-11 | — | — | EP | disclosed |
| US-8080571-B2 | Tricyclic angiotensin II agonists | VICORE PHARMA AB (SE) | 2011-12-20 | — | — | US | disclosed |
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | VICORE PHARMA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | AGTR1, AGTR2, NPY2R | AGTR2 2/4885AGTR1 1/4885CYP2C9 1541/4885 |
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | AGTR2 1/4885AGTR1 2/4885CYP2C9 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.